(Q35217592)

7 August 2017

1 reference

title

Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer (English)

1 reference

7 August 2017

1 reference

Susan J Edwards

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Seminars in Oncology Nursing

7 August 2017

published in

1 reference

7 August 2017

volume

19

1 reference

7 August 2017

issue

3 Suppl 1

1 reference

7 August 2017

page(s)

19-39

1 reference

Future directions in the treatment of ovarian cancer

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Increasing the visibility of patient fatigue

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Helping patients manage cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Changing patient perceptions of the side effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Fatigue in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Changes in self-concept and body image during alopecia induced cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Psychological sequelae and alopecia among women with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Factors influencing oral mucositis in patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Oral care for patients with cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

The symptom experience of mucositis, stomatitis, and xerostomia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Assessment and management of chemotherapy-induced mucositis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Understanding peripheral neuropathy in patients with cancer: background and patient assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Acute hypersensitivity reactions to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Clinical features of hypersensitivity reactions to carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Ethical issues in pain management

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

Barriers to effective cancer pain management: a survey of hospitalized cancer patients in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

The relationship of gender to pain

1 reference

https://api.crossref.org/works/10.1016%2FS0749-2081%2803%2900059-7

7 January 2021

10.1016/S0749-2081(03)00059-7

Identifiers

DOI

1 reference

7 August 2017

1 reference